Target
ZNRF3 E3 ubiquitin ligase
Description
ADCC-Enhanced anti-ZNRF3 E3 ubiquitin ligase (lgG-Ab2) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Short Bowel Syndrome; Osteoporosis; Diabetes; Neurodegenerative Diseases; Mucositis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ZNRF3 E3 ubiquitin ligase antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
ZNRF3 E3 ubiquitin ligase
Background
The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of β-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling.
Alternative Names
ZNRF3; ZNRF3 E3 ubiquitin ligase
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with ZNRF3 include Adrenal Carcinoma and Skin Carcinoma.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Function
E3 ubiquitin protein ligase mediates the ubiquitination and degradation of the Wnt receptor complex Frizzled and LRP6, and acts as a negative regulator of the Wnt signaling pathway. Acts on canonical and non-canonical Wnt signaling pathways. By inhibiting the Wnt signaling pathway, it has a tumor suppressor effect in the intestinal stem cell area, thereby detecting the size of the intestinal stem cell area. Together with RSPO2 and RNF43, it constitutes a master switch that controls branch specifications (based on similarity).
Post-translational modifications
1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
The ZNRF3 antibody can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis.
Antibody Indication
Short Bowel Syndrome; Osteoporosis; Diabetes; Neurodegenerative Diseases; Mucositis
